On January 19, 2022 Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, has reported the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, which was developed by Professor Stephen Neidle and his team from the UCL School of Pharmacy (Press release, UCLB, JAN 19, 2022, View Source [SID1234605585]). The license agreement was carried out by UCL Business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. QN-302 was also supported by the UCL Technology Fund, and in the earlier years, in part by Cancer Research UK funding.